Nutrineal Pd 4 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Nutrineal Pd 4 is used as part of amino‑acid based nutritional support for patients with complex metabolic needs.

• Post‑operative recovery: helps maintain nitrogen balance and supports tissue repair.
• Chronic kidney disease requiring dialysis: supplies essential amino acids that are not adequately removed by dialysis.
• Severe malnutrition or cachexia: contributes to protein synthesis and energy provision.
• Inborn‑born metabolic disorders: provides a defined mixture of amino acids for metabolic control.

• The formulation delivers a balanced mixture of essential and non‑essential amino acids directly to the peritoneal cavity, where they are absorbed into the bloodstream. These amino acids serve as substrates for protein synthesis, support nitrogen balance, and participate in metabolic pathways that sustain cellular function and tissue repair.

Adverse reactions are reported infrequently but may occur with intraperitoneal amino‑acid solutions.

Common Side Effects

• Mild abdominal discomfort or distension.
• Transient nausea or vomiting.
• Localized irritation at the infusion site.
• Low‑grade fever.
• Mild electrolyte shifts (e.g., potassium).

Serious or Rare Side Effects

• Peritoneal infection (peritonitis).
• Severe allergic reaction or anaphylaxis.
• Significant electrolyte imbalance.
• Metabolic acidosis.
• Hyperammonemia.
• Unexpected rise in serum amino‑acid levels.

When using Nutrineal Pd 4, clinicians should assess patient suitability and monitor relevant clinical parameters.

• Renal function: evaluate baseline creatinine and adjust therapy as needed.
• Hepatic function: monitor liver enzymes for potential metabolic impact.
• Electrolyte balance: check serum electrolytes regularly.
• Infection risk: observe for signs of peritonitis during intraperitoneal administration.
• Nutritional status: ensure the formulation matches the patient’s overall protein goals.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Amino‑acid solutions can interact with other intravenous therapies and affect laboratory measurements.

Major Interactions (Avoid)

• High‑dose potassium supplements: may exacerbate hyperkalemia when combined with amino‑acid infusion.
• Certain nephrotoxic antibiotics (e.g., aminoglycosides): increased risk of renal injury.

Moderate Interactions (Monitor Closely)

• Loop diuretics: can alter electrolyte balance during therapy.
• Insulin therapy: amino acids may affect glucose metabolism, requiring dose adjustments.
• Blood‑type compatible blood products: concurrent infusion may affect plasma amino‑acid measurements.
• Parenteral lipid emulsions: may require timing adjustments to avoid precipitation.